Mevalonic Acid Is Limiting for N-Linked Glycosylation and Translocation of the Insulin-like Growth Factor-1 Receptor to the Cell Surface
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Depletion of mevalonic acid (MVA), obtained by inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase using lovastatin, depressed the biosynthesis of dolichyl-phosphate and the rate of N-linked glycosylation and caused growth arrest in the melanoma cell line SK-MEL-2. The growth arrest was partially prevented by addition of high concentrations of insulin-like growth factor-1 (IGF-1) to the cells, indicating that MVA depletion may inhibit cell growth through decreasing the number of IGF-1 receptors (IGF-1R) at the cell surface. Such a decrease in receptor number might be a result of a lowered translocation of de novo synthesized receptors to the cell membrane which in turn might be a result of a decreased N-linked glycosylation of the receptor proteins. We could also demonstrate that IGF-1R became underglycosylated and that the amount of de novo synthesized IGF-1R proteins at the cell membrane was drastically decreased upon MVA depletion. Analysis of receptor proteins cross-linked with IGF-1, as well as binding assays and immunocytostaining confirmed that the number of functional membrane-bound IGF-1R was substantially reduced. The N-linked glycosylation and the expression of de novo synthesized IGF-1R proteins at the cell surface as well as the number of IGF-1 binding sites were completely restored upon replenishment of MVA. These effects of MVA were efficiently abrogated by the glycosylation inhibitor tunicamycin. The translocation of IGF-1R to the cell membrane was shown to take place just prior to initiation of DNA synthesis in arrested cells stimulated with MVA. Additionally, there was a clear correlation between IGF-1 binding and initiation of DNA synthesis with regard to the MVA dose requirement. It was confirmed that inhibition of HMG-CoA reductase activity and N-linked glycosylation also depressed the expression of functional IGF-1R in other cell types (i.e. hepatoblastoma cells and colon cancer cells). Our data suggest that this mechanism is involved in MVA-regulated cell growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Hart, G. W. (1992) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(92)90134-x · Cited by 193
Cited by
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Samani, A. A., Yakar, S., LeRoith, D., & Brodt, P. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0001 · Cited by 1,005
The interplay between cell signalling and the mevalonate pathway in cancer
Mullen, P. J., Yu, R., Longo, J., Archer, M. C., & Penn, L. Z. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.76 · Cited by 699
The dolichol pathway of N-linked glycosylation
Burda, P., & Aebi, M. (1999) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(98)00127-5 · Cited by 651
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer
Graaf, M. R., Richel, D. J., van Noorden, C. J. F., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.06.010 · Cited by 300
A mouse model for Zellweger syndrome
Baes, M., Gressens, P., Baumgart, E., Carmeliet, P., Casteels, M., Fransen, M., Evrard, P., Fahimi, D., Declercq, P. E., Collen, D., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-49 · Cited by 275
Lalancette-Hébert, M., Swarup, V., Beaulieu, J. M., Bohacek, I., Abdelhamid, E., Weng, Y. C., Sato, S., & Kriz, J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1498-12.2012 · Cited by 251
“Namely, it has been established that N-glycosylation is required for proper expression of IGF-R1 on the cell surface (Carlberg et al., 1996).”
BackgroundEdison, R. J., & Muenke, M. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30386 · Cited by 206
“1) [Brown and Goldstein, 1980; Carlberg et al., 1996; Brockhausen et al., 1998; Kelley andHerman, 2001;McMahon et al., 2002; Turunen et al., 2002; Muratani and Tansey, 2003; Roskoski, 2003].”
BackgroundTargeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor
Mantha, A. J., Hanson, J. E. L., Goss, G., Lagarde, A. E., Lorimer, I. A., & Dimitroulakos, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1951 · Cited by 101
Faust, P. L. (2003) · Journal of Comparative Neurology · doi:10.1002/cne.10699 · Cited by 71
Martínez-Botas, J. (2001) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(01)00125-1 · Cited by 57
(2010) · PubMed · Cited by 38
Metadata
- Authors
- Carlberg, M., Dricu, A., Blegen, H., Wang, M., Hjertman, M., Zickert, P., Höög, A., & Larsson, O.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1996-07
- Volume
- 271
- Issue
- 29
- Pages
- 17453-17462
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1984904066
- Cited by
- 135
- References
- 3
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.